BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

...The generic flupirtine is a non-opioid analgesic marketed to treat chronic pain and orthopedic pain. Meda AB...
BioCentury | Feb 15, 2016
Company News

Meda, Mylan deal

...acquire specialty pharma Meda for SEK165 per share in cash and stock. The deal values Meda...
...deal was announced. Mylan said Meda’s board has recommended that Meda shareholders approve the deal. Meda’s...
...is expected to close in 3Q16. Mylan had $9.4 billion in total 2015 revenue, and Meda...
BioCentury | Feb 11, 2016
Company News

Mylan acquiring Meda

...Generics company Mylan N.V. (NASDAQ:MYL) will acquire Meda AB (SSE:MEDAA) for about SEK83.6 billion ($9.9 billion) in...
...is a 92% premium over Meda's Wednesday close. The deal was announced after market hours. Meda...
...than 2,000 products. Mylan said Meda's board has recommended that Meda shareholders approve the deal. Meda...
BioCentury | Sep 14, 2015
Company News

Breckenridge sales and marketing update

...Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the...
BioCentury | May 18, 2015
Company News

GlaxoSmithKline, The ALS Association, Harvard, Massachusetts General Hospital deal

...Potiga from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Laval, Quebec), which has a license from Meda AB...
BioCentury | Mar 2, 2015
Clinical News

Dymista azelastine/fluticasone regulatory update

...FDA approved an sNDA from Meda for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients...
...in a single nasal spray delivery device -- for the indication in patients ages >=12. Meda...
...East, Africa, Asia, Europe, Japan, Brazil, South Korea and Australia. Cipla Ltd. , Mumbai, India Meda AB...
BioCentury | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Potassium channel

...treatment. Next steps could include testing the M-type channel openers in different models of stroke. Meda AB...
BioCentury | Feb 9, 2015
Company News

BioDelivery, Meda deal

...Meda returned North American rights to Onsolis fentanyl buccal soluble film to BioDelivery. Meda received rights...
...of two appearance issues raised by FDA. The financial terms between Meda and BioDelivery allow Meda...
...share in the proceeds of any new North American partnership for Onsolis. According to BioDelivery, Meda...
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...AMPA glutamate receptor (GRIA; GLUR) PAM Phase II Respiratory distress syndrome (RDA) Samyang Corp. (KSE:000070) Meda AB...
BioCentury | Nov 24, 2014
Company News

Rottapharm Madaus, Meda deal

...$2.1 billion) in cash and 30 million shares valued SEK2.9 billion ($406.4 million) based on Meda’s...
...day before the acquisition closed (see BioCentury, Aug. 4). Rottapharm Madaus Group , Monza, Italy Meda AB...
Items per page:
1 - 10 of 319
BioCentury | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

...The generic flupirtine is a non-opioid analgesic marketed to treat chronic pain and orthopedic pain. Meda AB...
BioCentury | Feb 15, 2016
Company News

Meda, Mylan deal

...acquire specialty pharma Meda for SEK165 per share in cash and stock. The deal values Meda...
...deal was announced. Mylan said Meda’s board has recommended that Meda shareholders approve the deal. Meda’s...
...is expected to close in 3Q16. Mylan had $9.4 billion in total 2015 revenue, and Meda...
BioCentury | Feb 11, 2016
Company News

Mylan acquiring Meda

...Generics company Mylan N.V. (NASDAQ:MYL) will acquire Meda AB (SSE:MEDAA) for about SEK83.6 billion ($9.9 billion) in...
...is a 92% premium over Meda's Wednesday close. The deal was announced after market hours. Meda...
...than 2,000 products. Mylan said Meda's board has recommended that Meda shareholders approve the deal. Meda...
BioCentury | Sep 14, 2015
Company News

Breckenridge sales and marketing update

...Breckenridge launched azelastine nasal solution, a generic of Astelin from Meda AB (SSE:MEDAA, Solna, Sweden), in the...
BioCentury | May 18, 2015
Company News

GlaxoSmithKline, The ALS Association, Harvard, Massachusetts General Hospital deal

...Potiga from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Laval, Quebec), which has a license from Meda AB...
BioCentury | Mar 2, 2015
Clinical News

Dymista azelastine/fluticasone regulatory update

...FDA approved an sNDA from Meda for Dymista azelastine/fluticasone to treat seasonal allergic rhinitis in patients...
...in a single nasal spray delivery device -- for the indication in patients ages >=12. Meda...
...East, Africa, Asia, Europe, Japan, Brazil, South Korea and Australia. Cipla Ltd. , Mumbai, India Meda AB...
BioCentury | Feb 19, 2015
Distillery Therapeutics

Therapeutics: Potassium channel

...treatment. Next steps could include testing the M-type channel openers in different models of stroke. Meda AB...
BioCentury | Feb 9, 2015
Company News

BioDelivery, Meda deal

...Meda returned North American rights to Onsolis fentanyl buccal soluble film to BioDelivery. Meda received rights...
...of two appearance issues raised by FDA. The financial terms between Meda and BioDelivery allow Meda...
...share in the proceeds of any new North American partnership for Onsolis. According to BioDelivery, Meda...
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...AMPA glutamate receptor (GRIA; GLUR) PAM Phase II Respiratory distress syndrome (RDA) Samyang Corp. (KSE:000070) Meda AB...
BioCentury | Nov 24, 2014
Company News

Rottapharm Madaus, Meda deal

...$2.1 billion) in cash and 30 million shares valued SEK2.9 billion ($406.4 million) based on Meda’s...
...day before the acquisition closed (see BioCentury, Aug. 4). Rottapharm Madaus Group , Monza, Italy Meda AB...
Items per page:
1 - 10 of 319